Drug Profile
Research programme: cyclo-oxygenase-2 inhibitors - Euclises Pharmaceuticals/Guangzhou Institutes of Biomedicine and Health
Alternative Names: Euclicoxibs®Latest Information Update: 28 Jan 2019
Price :
$50
*
At a glance
- Originator Euclises Pharmaceuticals
- Developer Euclises Pharmaceuticals; Guangzhou Institutes of Biomedicine and Health
- Class
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jan 2019 No recent reports of development identified for preclinical development in Cancer in China
- 28 Jan 2019 No recent reports of development identified for preclinical development in Cancer in USA
- 03 Dec 2014 Euclises Pharmaceuticals enters into a development agreement with Guangzhou Institutes of Biomedicine and Health for the development of COX-2 inhibitors